Growth in patients with the salt-wasting form of congenital adrenal hyperplasia during the first two years of life;Crescimento de pacientes com hyperplasia congênita das supra-renais, forma perdedora de sal, nos dois primeiros anos de vida

Revista Brasileira de Saude Materno Infantil

Volumn 9, Issue 4, 2009, Pages 415-421

  Mendes dos Santos, Carolina T ^a   de Lemos Marini, Sofia H V ^a   Baptista, Maria Tereza M ^a   Guerra Junior, Gil ^a   De Mello, Maricilda P ^a   Morcillo, André M ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Adrenal glands; Adrenal hyperplasia; Congenital; Growth

Indexed keywords

EID: 74949083481     PISSN: 15193829     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1519-38292009000400005     Document Type: Article

References (21)

1. American Academy of Pediatrics. Technical report: Congenital adrenal hyperplasia. Pediatrics. 2000; 106: 1511-8.
2. Nguyen AT, Brown JJ, Warne GL. Growth in congenital adrenal hyperplasia. Indian J Pediatr. 2006; 73: 89-93.
3. New MI. An update of congenital adrenal hyperplasia. Ann N Y Acad Sci. 2004; 1038: 14-43.
4. Pang S. Congenital adrenal hyperplasia. Endocrinol Metab Clin North Am. 1997; 26: 853-91.
5. Forest MG. Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod Update. 2004; 10: 469-85.
6. Miller WL. Genetics, diagnosis, and management of 21-hydroxilase deficiency. J Clin Endocrinol Metab. 1994; 78: 241-6.
7. Girgis R, Winter JSD. The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyper-plasia. J Clin Endocrinol Metab. 1997; 82:3 926-9.
8. Eugster EA, Dimeglio LA, Wright JC, Freidenberg GR, Seshadri R, Pescovitz OH. Height outcome in congenital adrenal hyperplasia caused by 21 hydroxylase deficiency: a meta-analysis. J Pediatr. 2001; 138: 26-32.
9. Cameron FJ, Kaymakci B, Byrt EA, Ebeling PR, Warne GL, WalkJD. Bone mineral density and body composition in congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1995; 80: 2238-43.
10. Cornean RE, Hindmarsh PC, Brook CG. Obesity in 21-hydroxylase deficient patients. Arch Dis Child. 1998; 78: 261-3.
11. Migeon CJ, Donohoue PA. Congenital adrenal hyperplasia caused by 21-hydroxylase deficiency. Its molecular basis and its remaining therapeutic problems. Endocrinol Metab Clin North Am. 1991; 20: 277-96.
12. Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet. 2005; 365: 2125-36.
13. Schwartz RP. Back to basics: early diagnosis and compliance improve final height outcome in congenital adrenal hyperplasia. J Pediatr. 2001; 138: 3-5.
14. Manoli I, Kanaka-Gantenbein CH, Voutetakis A, Maniati-Christidi M, Dacou-Voutetakis A. Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome. Clin Endocrinol (Oxf). 2002; 57: 669-76.
15. Savage MO, Scommegna S, Carroll PV, Ho JT, Monson JP, Besser GM, Grossman AB. Growth in disorders of adrenal hyperfunction. Horm Res. 2002; 58 (suppl 1): 39-43.
16. Van der Kamp HJ, Otten BJ, Buitenweg N, De Munick Keiser-Schrama SMPF, Oostdijk W, Jansen M, Delemarre-de-Waal HA, Vulsma T, Wit JM. Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients. Arch Dis Child. 2002; 87: 139-44.
17. Lemos-Marini SHV, Guerra-Júnior G, Morcillo AM, Baptista MTM, Silva LO, Maciel-Guerra AT. Hiperplasia congênita das supra-renais por deficiência da 21-hidroxilase: altura final de 27 pacientes com a forma clássica. Arq Bras Endocrinol Metab. 2005; 49: 902-7.
18. Hargitai G, Sólyom J, Battelino T, Lebl J, Pribilincová Z, Hauspie R, Kovács J, Waldhauser F, Frisch H and the MEWPE-CAH study group. Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Results of a multicenter study. Horm Res. 2001; 55: 161-71.
19. National Center for Health Statistics. 2000 CDC growth charts: United States. [cited on 2007 mar 8] Available from: http://www.cdc.gov/growthcharts/
20. Ramos CCA, Bento LR, Gonçalves EM, De-Mello MP, Baptista MTM, Lemos-Marini SHV, Guerra-Junior G. Avaliação do crescimento, do controle laboratorial e da corticoterapia em um grupo de pacientes com a forma clássica da deficiência da 21-hidroxilase. Rev Paul Pediatr. 2007; 25: 317-23.
21. Gussinye M, Potau N, Vicens-Calvet E, Albisu MA, Yeste D, Ibanez L, Audí L, Carrascosa A. Adult height, pattern of growth and pubertal development in patients with congenital adrenal hyperplasia, salt losing form. Med Clin (Barc). 1997; 108: 87-90.